开放式创新演讲报告.pptVIP

3. ‘Contracting for innovation’ partnerships with biotech-like governance Example: Pfizer-UCSF partnership described by Pfizer as motivated by “open innovation” (in addition to $85m, open research centre near UCSF) Funding used to hire postdocs who can freely work in both academic and industry labs “The Pfizer and UCSF researchers can visit each other’s labs, conduct experiments together and participate in joint team-meetings” (quote from UCSF alliance manager, O’Brien 2011) Master agreement defines clear IP rights, milestone payments, IP jointly owned, with Pfizer having an exclusive (time limited) option, terms of licence negotiated More focused, based on research at a more advanced stage than previous partnerships and focused on protein biologics, no conflict between the objective of drug development and academic mission to publish 3. ‘Contracting for innovation’ partnerships with biotech-like governance Governance designed to promote relational mode of decision-making: Joint governance of project selection and continued funding Oversight committee with equal membership of Pfizer and UCSF scientists, all with voting power Consensus norm developed in early decisions Partnership terms have incentivized senior scientists at UCSF to solicit proposals 5 of initial 8 technologies funded from department heads, chiefs at hospital, or center directors at UCSF 3. ‘Contracting for innovation’ partnerships with biotech-like governance Governance designed to promote relational mode of decision-making: Office of innovation, technology and alliances heavily involved, facilitating on-going project work, e.g. budget management, locating resources, etc. Project work over the first two years has involved the utilization of scientific facilities at both Pfizer and UCSF Co-location advantages, monthly meetings, joint running of in vivo experiments Evidence of a true “collaboration”, rather than perhaps more typical “throw it over the wall” type of licensing 3. ‘Contracting for